Overview

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Status:
Terminated

Trial end date:
2019-08-13

Target enrollment:

Participant gender:

Summary

The objective of this study was to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy

Phase:

Phase 2

Details

Lead Sponsor:

Bayer

Treatments:

Hormones
Radium Ra 223 dichloride
Succinylcholine